Anacor Pharmaceuticals (NASDAQ:ANAC) will host an Investor Day for institutional investors and research analysts on Monday August 5, 2013 from approximately 12:00 p.m. to 3:30 p.m. ET in New York, New York. The meeting will focus on the development of its two lead compounds - tavaborole for onychomycosis and AN2728 for atopic dermatitis. Experts in the fields of podiatry and dermatology will be featured speakers at the meeting.
A live webcast of the event will be available on the Investor Relations page of Anacor’s website at
For more information, contact DeDe Sheel, Anacor Pharmaceuticals Director of Investor Relations and Corporate Communications.
About Anacor Pharmaceuticals
Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered eight compounds that are currently in development. Its two lead product candidates are topically administered dermatologic compounds — tavaborole, a topical antifungal for the treatment of onychomycosis, and AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of atopic dermatitis and psoriasis. In addition to its two lead programs, Anacor has discovered three other wholly-owned clinical product candidates — AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365 an antibiotic for the treatment of infections caused by Gram-negative bacteria. We have discovered three other compounds that we have out-licensed for further development — two compounds for the treatment of animal health indications that are licensed to Eli Lilly and Company and AN5568, also referred to as SCYX-7158, for human African trypanosomiasis (HAT, or sleeping sickness), which is licensed to Drugs for Neglected Diseases initiative, or DNDi. We also have a pipeline of other internally discovered topical and systemic boron-based compounds in development. For more information, visit